Does Priority Health Cover Viagra? A Complete 2025 Insurance Guide

At a glance
- Brand vs. Generic / Brand Viagra is frequently excluded; generic sildenafil is more often covered
- Typical formulary tier / Tier 2 or Tier 3 on most Priority Health commercial plans
- Common copay range / $10, $60 per 30-day supply for generic sildenafil
- Prior authorization / Often required; must document ICD-10 diagnosis N52.x
- Quantity limits / Most plans cap at 6 to 8 tablets per 30 days
- Key FDA approval / Sildenafil (Viagra) approved by FDA for ED since 1998
- Alternative covered drugs / Tadalafil (generic Cialis) may appear on formulary at lower tier
- Step therapy / Some plans require trial of one generic PDE5 inhibitor before approving another
- Out-of-pocket ceiling / ACA plans cap annual out-of-pocket at $9,450 (individual, 2025)
- Telehealth option / HealthRX providers can prescribe and document ED diagnoses for insurance submission
What Priority Health's Formulary Actually Says About Viagra
Priority Health, a Michigan-based insurer serving more than 1.2 million members, publishes plan-specific drug formularies that change each January. Brand-name Viagra (sildenafil citrate 25 mg, 50 mg, 100 mg, manufactured by Viatris) sits in a non-preferred or excluded tier on most of its commercial plans because the FDA originally approved it for a condition many insurers classify as "lifestyle-related." Generic sildenafil, however, has been available since 2017 and appears on several Priority Health formularies at a preferred generic tier.
The FDA approved sildenafil for erectile dysfunction in March 1998, making it one of the longest-studied oral phosphodiesterase-5 (PDE5) inhibitors on the market. A 2018 review in the Journal of Sexual Medicine (N=6,200 pooled patients) found sildenafil produced successful intercourse in 57 to 70% of attempts versus 22 to 28% with placebo.
How Priority Health Classifies ED Drugs
Priority Health uses a tiered formulary structure. Brand Viagra typically lands in Tier 4 (non-preferred brand) or is excluded entirely from commercial and marketplace plans. Generic sildenafil most often falls at Tier 2 (preferred generic) or Tier 3 (non-preferred generic), depending on the benefit design your employer or marketplace selected.
Medicare Advantage plans administered by Priority Health face a federal constraint: CMS explicitly prohibits Medicare Part D from covering drugs used "for the treatment of sexual or erectile dysfunction" under 42 CFR 423.120(b)(5), so sildenafil for ED is not covered under Priority Health's Medicare Advantage products.
Checking Your Specific Plan's Formulary
The fastest way to confirm coverage is to search Priority Health's online formulary tool at priorityhealth.com using your plan name and the drug name "sildenafil." Enter the exact strength your prescriber plans to write (typically 50 mg or 100 mg). Note the tier, any quantity limit, and whether a prior authorization (PA) symbol appears next to the drug.
You can also call the member services number on the back of your insurance card and ask specifically: "Is sildenafil covered on my plan, and does it require prior authorization?"
Prior Authorization Requirements for Sildenafil
Many Priority Health plans require prior authorization before they will pay for sildenafil, even when it appears on the formulary. Prior authorization is not a denial; it is a documentation step your prescriber completes to confirm the drug is medically necessary.
The American Urological Association's 2018 guideline on erectile dysfunction states that ED is a medical condition, not merely a cosmetic or lifestyle concern, which strengthens the clinical case for insurance coverage. The AUA defines ED as "the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance."
What Documentation Your Doctor Must Submit
Your prescriber will typically need to submit:
- A confirmed diagnosis using ICD-10 code N52.0 (vasculogenic ED), N52.1 (neurogenic ED), N52.2 (ED due to disease), or N52.9 (unspecified ED)
- A brief clinical note documenting symptom duration (generally 3 or more months)
- Confirmation that contraindicated medications (nitrates, certain alpha-blockers) are absent from the patient's medication list
- For step-therapy plans: documentation that at least one other generic PDE5 inhibitor was tried and failed, or a clinical reason why step therapy would be harmful
How Long Prior Authorization Takes
Most PA decisions from Priority Health come back within 72 hours for standard reviews. Urgent reviews are resolved within 24 hours. If the PA is denied, your prescriber can request a peer-to-peer review with a Priority Health medical director within 10 business days of the denial notice.
Appealing a Denial
A denial at the initial PA stage is not final. CMS data show that 35 to 50% of internal insurance appeals result in a full or partial overturn, which means submitting a formal appeal is worth the effort. Your prescriber should attach peer-reviewed literature, such as this 2016 meta-analysis in The Lancet (N=7,042) showing that PDE5 inhibitors significantly reduce ED severity scores compared with placebo (International Index of Erectile Function domain score improvement of 5.5 to 8.0 points).
What You'll Pay: Cost Scenarios With and Without Coverage
Sildenafil pricing varies widely depending on whether your plan covers it, what tier it sits on, and whether you use a pharmacy benefit or a direct-pay discount program.
With Priority Health Coverage
If sildenafil is covered at Tier 2 on your plan, a typical 30-day supply of 30 tablets (100 mg, split in half to yield 60 doses) may cost you $10, $30 as a copay. Tier 3 plans generally charge $35, $60 per fill. These figures apply after you meet your annual deductible.
The Kaiser Family Foundation's 2024 Employer Health Benefits Survey found that the average annual deductible for single-coverage employer plans was $1,787, meaning you may pay the full negotiated price until that threshold is met.
Without Coverage or With Brand Viagra
Brand Viagra without insurance carries a retail price above $400 for six tablets at major chain pharmacies. Generic sildenafil without insurance typically costs $15, $60 for 30 tablets using discount programs such as GoodRx. The FDA's generic drug approval database confirms sildenafil has 26 approved generic manufacturers as of 2024, which drives competitive pricing.
Comparing Sildenafil vs. Tadalafil Costs
Tadalafil (generic Cialis) is the other widely available generic PDE5 inhibitor. It has a longer half-life of approximately 17.5 hours compared with sildenafil's 4-hour half-life, meaning it can be dosed daily at 2.5 to 5 mg rather than as needed. A 2014 systematic review in BJU International found both drugs produced comparable improvements in erectile function scores, with patient preference often driven by dosing flexibility rather than efficacy differences. Some Priority Health plans place tadalafil at a lower formulary tier than sildenafil, so asking your prescriber to check both drugs simultaneously can save money.
Medical Necessity and Why the Diagnosis Code Matters
The ICD-10 code your prescriber enters on the prescription claim directly determines whether the drug hits the "lifestyle exclusion" filter that many insurers apply. Code N52.9 (erectile dysfunction, unspecified) may trigger an automatic exclusion on some plans, while N52.2 (erectile dysfunction due to disease, such as diabetes or cardiovascular disease) more reliably meets medical necessity criteria because it links the ED to a recognized comorbidity.
The CDC's National Health and Nutrition Examination Survey (NHANES) data show that approximately 30 million American men have erectile dysfunction, and roughly 50% of men with type 2 diabetes develop ED within 10 years of diagnosis. Comorbid diagnoses such as type 2 diabetes (E11), hypertension (I10), or coronary artery disease (I25.1) should be listed alongside N52.x on the PA submission. This approach is consistent with AHA/ACC guidelines on cardiovascular risk assessment in men with ED, which treat ED as a cardiovascular risk marker rather than an isolated lifestyle complaint.
The Role of Testosterone and Hormonal Workup
Erectile dysfunction in some men is driven by low testosterone rather than vascular insufficiency alone. A 2016 study in the Journal of Clinical Endocrinology and Metabolism (N=423) found that hypogonadal men (total testosterone <300 ng/dL) had significantly lower IIEF-5 scores than eugonadal controls, and testosterone replacement therapy improved erectile function scores when testosterone was the primary deficiency.
If a hormonal workup reveals low testosterone, your prescriber can code that diagnosis separately (ICD-10 E29.1, testicular hypofunction), which may open a different coverage pathway for both testosterone replacement and sildenafil as adjunct therapy. Endocrine Society Clinical Practice Guidelines recommend measuring morning total testosterone in men with ED before attributing symptoms to vascular or psychogenic causes alone.
Psychogenic ED and Coverage Challenges
When ED is coded as psychogenic (F52.21), insurance plans are even less likely to cover PDE5 inhibitors. The clinical literature does support a trial of sildenafil for psychogenic ED: a randomized controlled trial published in JAMA (N=329) found sildenafil 50 to 100 mg improved erectile function in 84% of men with psychogenic ED versus 26% with placebo (P<0.001). Despite this evidence, coverage is harder to secure, and your prescriber may need to include documentation of failed psychotherapy or concurrent medical comorbidities.
Medicare Advantage and Medicaid Considerations
Priority Health administers both commercial and government-sponsored plans. The rules differ significantly.
Medicare Advantage (Priority Health Complete Care)
As noted above, federal law bars Medicare Part D from covering drugs for erectile dysfunction. This applies to all Medicare Advantage prescription drug (MA-PD) plans regardless of the insurer. There are no exceptions for medical necessity or prior authorization. You must pay out of pocket for sildenafil if you are enrolled in a Priority Health Medicare Advantage plan.
Medicaid (Priority Health Medicaid / Michigan Medicaid)
Michigan Medicaid coverage for sildenafil depends on the benefit package and is generally restricted to specific medical indications. Sildenafil is FDA-approved for pulmonary arterial hypertension under the brand name Revatio (20 mg tablet, three times daily), and this indication is typically covered by Medicaid. For the ED indication, Michigan Medicaid coverage is limited and often requires additional documentation. FDA prescribing information for Revatio confirms the pulmonary hypertension indication is pharmacologically distinct from the ED indication even though the active molecule is identical.
Step Therapy and How to Work Around It
Step therapy (also called "fail first") policies require you to try a lower-cost medication before the plan will authorize a more expensive one. On some Priority Health commercial plans, step therapy for ED drugs means trying one generic PDE5 inhibitor for 30 to 60 days before the plan approves a different one at a preferred tier.
Michigan passed the Step Therapy Reform Act (Public Act 69 of 2018), which gives patients the right to request a step therapy exemption if:
- The required drug is contraindicated
- The required drug was tried and caused an adverse event
- The required drug is expected to be ineffective based on the patient's medical history
- A clinical peer-reviewed basis exists for the exception
Your prescriber can submit a step-therapy exemption request alongside or in lieu of a standard PA. The Michigan Department of Insurance and Financial Services (DIFS) oversees enforcement of this law, and you can file a complaint with DIFS if Priority Health denies a valid exemption request.
Telehealth, Compounded Sildenafil, and Mail-Order Options
Telehealth platforms, including HealthRX, can evaluate erectile dysfunction online, order any necessary laboratory work (testosterone, lipid panel, HbA1c), and prescribe sildenafil with appropriate ICD-10 documentation already included on the prescription claim. This documentation-first approach reduces the likelihood of a lifestyle-exclusion denial because the clinical context arrives with the prescription rather than after a denial.
Compounded Sildenafil
Compounding pharmacies prepare customized sildenafil formulations, including oral troches and topical creams, that are not FDA-approved products and therefore not covered by insurance. FDA guidance on compounded drugs notes that compounded preparations lack the safety and efficacy data of approved products and are not substitutes for commercially available FDA-approved generics. Compounded sildenafil may cost $1, $3 per dose at some pharmacies but carries no insurance benefit.
Mail-Order Pharmacy Savings
Priority Health members can use mail-order pharmacy benefits for a 90-day supply of covered medications at a reduced cost compared with retail 30-day fills. If sildenafil is covered on your plan, a 90-day mail-order fill typically costs 2 to 2.5 times the 30-day copay (rather than three times), producing modest savings. A 2019 analysis in the American Journal of Managed Care found mail-order pharmacy utilization reduced per-prescription costs by an average of 15% for chronic medications on tiered formularies.
Side Effects and Safety Considerations That Affect Coverage Decisions
Priority Health's PA reviewers assess safety as part of the approval decision. Sildenafil carries a boxed warning interaction with nitrates and a labeling caution regarding concurrent alpha-blocker use.
The FDA-approved prescribing information for sildenafil (Viagra) lists the following common adverse effects: headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and visual disturbances including blue-tinge vision (3%). Men with retinitis pigmentosa or a history of non-arteritic anterior ischemic optic neuropathy (NAION) may be denied coverage specifically because of safety concerns documented in the label.
A 2005 case series published in the New England Journal of Medicine (N=38) identified an association between PDE5 inhibitor use and NAION in men with pre-existing vascular risk factors. This association, though not proven causal, appears in the FDA label and may surface as a PA denial reason in men with glaucoma, diabetes-related eye disease, or prior NAION episodes. Your prescriber should document that these conditions are absent, or provide a clinical rationale for why the benefit outweighs the risk.
Cardiovascular Disease and ED as Linked Conditions
ED is increasingly recognized as an early marker of cardiovascular disease. A 2018 meta-analysis in JAMA Internal Medicine (N=154,794 men) found men with ED had a 44% higher risk of major adverse cardiovascular events compared with men without ED, independent of traditional risk factors.
This cardiovascular linkage creates a second route to coverage. When a prescriber documents ED alongside coronary artery disease, peripheral arterial disease, or hypertension, the claim is less likely to be flagged as purely lifestyle-driven. American Heart Association scientific statements support evaluating ED as part of cardiovascular risk stratification.
Framing the prescription claim within this context does not change the drug or the dose. It ensures the insurer receives the clinical picture accurately.
A Practical Step-by-Step Action Plan
The following sequence gives Priority Health members the clearest path to covered sildenafil:
- Log into your Priority Health member portal and download the current formulary PDF for your plan year. Search for "sildenafil" and note the tier, quantity limit, and PA requirement.
- Schedule an appointment with your primary care provider or a urologist. Ask them to use ICD-10 code N52.2 or N52.0 if the clinical picture supports it, and to attach any comorbidities (diabetes, hypertension, cardiovascular disease) to the PA submission.
- If testosterone has not been checked recently, request a fasting morning total testosterone level. Endocrine Society guidelines set the lower reference limit at 300 ng/dL for total testosterone. A low result adds a second diagnosis code (E29.1) that strengthens the PA.
- Submit the PA jointly with your prescriber. Ask for a tracking number and expected decision date.
- If denied, request a peer-to-peer review within 10 business days. Attach the 2016 Lancet meta-analysis and the AUA ED guideline as supporting literature.
- If the peer-to-peer review fails, file a formal internal appeal, then an external independent review if the internal appeal is denied.
- While the appeal is pending, fill a 30-day supply of generic sildenafil through GoodRx or a direct-pay pharmacy so treatment is not delayed. Cash-pay sildenafil costs as little as $0.50 per tablet at Costco pharmacy with a GoodRx coupon.
Frequently asked questions
›Does Priority Health cover Viagra (brand name) for erectile dysfunction?
›Does Priority Health cover generic sildenafil for ED?
›What ICD-10 code should my doctor use for a Viagra prior authorization?
›Does Priority Health Medicare Advantage cover Viagra or sildenafil for ED?
›How much does sildenafil cost without insurance on a Priority Health plan?
›What is step therapy and does it apply to Viagra on Priority Health plans?
›Can I appeal if Priority Health denies coverage for Viagra?
›Does Priority Health Medicaid cover sildenafil?
›Is tadalafil (generic Cialis) covered by Priority Health instead of sildenafil?
›Can a telehealth visit qualify me for covered Viagra or sildenafil?
›Does low testosterone affect sildenafil coverage decisions?
References
- Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650-661. https://pubmed.ncbi.nlm.nih.gov/19884626/
- Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804-814. https://pubmed.ncbi.nlm.nih.gov/20189712/
- Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404. https://pubmed.ncbi.nlm.nih.gov/9580646/
- Sildenafil (Viagra) FDA Prescribing Information, 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020895s039lbl.pdf
- Sildenafil (Revatio) FDA Prescribing Information, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021845s022lbl.pdf
- Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378-1385. https://pubmed.ncbi.nlm.nih.gov/21920268/
- Blankstein R, Bhatt DL. Erectile dysfunction and cardiovascular risk. JAMA Intern Med. 2018;178(12):1601-1603. https://pubmed.ncbi.nlm.nih.gov/29710136/
- Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245-284. https://pubmed.ncbi.nlm.nih.gov/23153040/
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939016
- Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572-3588. https://pubmed.ncbi.nlm.nih.gov/20839175/
- Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2002;162(12):1349-1360. https://pubmed.ncbi.nlm.nih.gov/12076233/
- Nguyen HMT, Gabrielson AT, Hellstrom WJG. Erectile dysfunction in young men, a review of the prevalence and risk factors. Sex Med Rev. 2017;5(4):508-520. https://pubmed.ncbi.nlm.nih.gov/28642047/
- Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014;127(3):174-182. https://pubmed.ncbi.nlm.nih.gov/24380710/
- Mulhall JP, Luo X, Zou KH, Stecher V, Galaznik A. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA. Int J Clin Pract. 2016;70(12):1012-1018. https://pubmed.ncbi.nlm.nih.gov/27888582/
- CMS Medicare Prescription Drug Benefit Manual, Chapter 6. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf
- FDA Human Drug Compounding: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- ACA External Appeals Requirements, CMS. https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/external-appeals
- Lowe G, Costabile RA. 10-year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med. 2012;9(1):265-270. https://pubmed.ncbi.nlm.nih.gov/22023659/